Panosome

Panosome is a private, pre-clinical stage biotech company leveraging its unique VAST platform to generate antibodies against challenging antigen classes. Spun out from the German Cancer Research Center (DKFZ), the company's core technology utilizes a dense, nanoparticle-forming surface array to elicit potent immune responses. Its initial strategy is to partner with pharmaceutical companies and develop immunotherapeutics in areas like oncology, targeting antigens that have eluded conventional antibody discovery methods.

VAST platform: A proprietary antibody generation system based on a highly immunogenic, recombinant surface array derived from the African Trypanosome. It displays over ten million proteins and can be conjugated with diverse antigens (proteins, peptides, small molecules, sugars, lipids) to elicit potent immune responses, with the option to form scalable nanoparticles.

Panosome competes with established antibody discovery platforms (e.g., phage/yeast display, hybridoma) and newer technologies (e.g., single B-cell cloning, synthetic libraries). Its differentiation lies in its unique biological inspiration for potent immunogenicity, specifically aimed at antigen classes where these other methods often fail. Competition in targeted oncology, especially for antigens like MUC1, is intense from both large biopharma and other biotechs.